BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 28095411)

  • 1. Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia.
    Simms KT; Hall M; Smith MA; Lew JB; Hughes S; Yuill S; Hammond I; Saville M; Canfell K
    PLoS One; 2017; 12(1):e0163509. PubMed ID: 28095411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.
    Kim JJ; Wright TC; Goldie SJ
    JAMA; 2002 May; 287(18):2382-90. PubMed ID: 11988059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
    Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
    Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Results and cost evaluation of triage with high risk HPV test in cervical cancer screening. A pilot study in Piedmont (North-West Italy)].
    Magnani C; Gillio Tos A; De Marco L; Calvia M; Cipelletti A; Bestagini P; Pagano E; Segnan N; Ronco G
    Epidemiol Prev; 2012; 36(2):88-94. PubMed ID: 22706358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study.
    Cox JT; Castle PE; Behrens CM; Sharma A; Wright TC; Cuzick J;
    Am J Obstet Gynecol; 2013 Mar; 208(3):184.e1-184.e11. PubMed ID: 23174289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
    Tay SK; Lin LE; Goh RC
    Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
    BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
    Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
    Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies.
    Pista A; Costa C; Saldanha C; Moutinho JAF; Moutinho JM; Arrobas F; Catalão C; Kempers J
    BMC Public Health; 2019 Feb; 19(1):235. PubMed ID: 30808324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].
    Ronco G; Confortini M; Maccallini V; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(5 Suppl 2):e1-e33. PubMed ID: 23139163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
    Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
    Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
    Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic analysis of human papillomavirus triage, repeat cytology, and immediate colposcopy in management of women with minor cytological abnormalities in Sweden.
    Ostensson E; Fröberg M; Hjerpe A; Zethraeus N; Andersson S
    Acta Obstet Gynecol Scand; 2010 Oct; 89(10):1316-25. PubMed ID: 20846064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology.
    Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M
    Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Sequential Rounds of Cervical Cancer Screening on Management of HPV-positive Women: A 15-year Population-based Cohort Study from China.
    Xu XQ; Rezhake R; Hu SY; Chen F; Zhang X; Pan QJ; Zhang WH; Ma JF; Qiao YL; Zhao FH; Cruickshank M
    Cancer Prev Res (Phila); 2021 Mar; 14(3):363-372. PubMed ID: 33303694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.